Alerta

LEVODOPA DOSING REGIMEN

Resumen de: US2025152543A1

The invention is a method for treating levodopa naïve patients with Parkinson's disease by orally administering a controlled release levodopa formulation twice a day to the levodopa naïve patient and the method provides an improvement of a patient's motor state as determined by patient's Parkinson's disease diary, provides a reduction of from about 10%-40% in the patient's tremor, dyskinesia, and/or mobility and/or provides a reduction in the patient's Movement Disorders Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores by at least 3 points.

LEVODOPA NASAL SPRAY, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: WO2025098365A1

Disclosed are a levodopa nasal spray, a preparation method therefor, and use thereof. The levodopa nasal spray comprises levodopa or a pharmaceutically acceptable salt thereof, an absorption enhancer, a suspending agent, an antioxidant, a wetting agent, and an antimicrobial agent. The levodopa nasal spray enhances the stability of levodopa, increases olfactory region deposition of the drug, improves nasal-to-brain delivery efficiency, can effectively treat Parkinson's disease while reducing the occurrence of symptom fluctuations, and has suitable viscosity.

NURR1:RXR ACTIVATING COMPOUNDS FOR SIMULTANEOUS TREATMENT OF SYMPTOMS AND PATHOLOGY OF PARKINSON'S DISEASE

Resumen de: US2025152590A1

The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeuties to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also able to treat the symptoms of such diseases and therefore represent a new treatment modality for ameliorating chronic and acute conditions. The compounds of the invention are capable of selectively potentiating the activity of the Nurr1:RXRα heterodimer, and are able to treat diseases or conditions associated with aberrant Nurr1:RXRα function. The invention further provides methods for treating neurodegenerative disorders by administration of Nurr1:RXRα activating agents.

LEVODOPA DOSING REGIMEN

Resumen de: US2025152539A1

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

METHOD FOR PREVENTING OR TREATING PARKINSON'S DISEASE

Resumen de: US2025152659A1

A method for preventing or treating Parkinson's disease including administering a patient in need thereof a pharmaceutical composition including a polypeptide, the peptide having an amino acid sequence I or II: I: FPGSDRF (SEQ ID NO: 1)-Z; II: X-FPGSDRF (SEQ ID NO: 1)-Z; S represents phosphorylated serine; X and Z independently represents an amino acid or an amino acid sequence; X is selected from F, (R)9 (SEQ ID NO: 2), (R)9-F (SEQ ID NO: 3), 6-aminohexanoic acid, 6-aminohexanoic acid-F, 6-aminohexanoic acid-(R)9 (SEQ ID NO: 2), 6-aminohexanoic acid-(R)9-F (SEQ ID NO: 3); and Z is selected from (G)n-RGD or A-(G)n-RGD (SEQ ID NO: 4), where n is an integer greater than or equal to 0, in the range of 0-10.

ENZYME CAPABLE OF DEGRADING AMYLOID-β, AND PHARMACEUTICAL COMPOSITION USING SAME

Resumen de: WO2025100469A1

According to the present invention, it is found that a snake venom metaloproteinase SVMP (snake venom metalloproteinase) from a snake belonging to the family Viperidae, the family Elapidae or the like decomposes Aβ and cuts the Aβ at an α-position to suppress the formation of Aβ fibrils. When a protein containing a metaloproteinase domain of SVMP is administered or a gene for the protein is introduced and is expressed in the brain, the formation of Aβ fibrils can be suppressed and consequently Alzheimer's disease can be treated.

METHODS OF TREATING GAUCHER DISEASE AND GBA-PARKINSON’S DISEASE

Resumen de: US2025152747A1

Provided herein are expression cassettes for expressing a transgene in a cell, wherein the transgene encodes a GCase polypeptide. Also provided are methods to treat Gaucher Disease or GBA-PD. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions, and kits for expressing an GCase polypeptide in an individual in need thereof.

LEVODOPA DOSING REGIMEN

Resumen de: US2025152542A1

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

LEVODOPA DOSING REGIMEN

Resumen de: US2025152540A1

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

LEVODOPA DOSING REGIMEN

Resumen de: US2025152541A1

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

ALPHA,ß-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

Resumen de: EP4553069A1

Provided in the present invention are an α,β-unsaturated amide compound, and a preparation method therefor, and a pharmaceutical composition and the use thereof. Specifically, provided in the present invention is a compound as represented by formula I, wherein the definition of each group is as described in the description. The compound can be used as a compound for improving cerebral blood flow and is used for preparing a pharmaceutical composition for treating neurodegenerative diseases such as Alzheimer's disease and vascular dementia and strokes.

SUSTAINED RELEASE-MICROSPHERE FORMULATION COMPRISING SEMAGLUTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PREPARATION METHOD THEREFOR

Resumen de: EP4552634A1

The present disclosure relates to a pharmaceutical composition useful for the prevention or treatment of diabetes, preservation of beta-cell function, hypertension, hyperlipidemia, obesity, non-alcoholic steatohepatitis, or neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, which includes a sustained-release microsphere containing semaglutide or a pharmaceutically acceptable salt thereof, a bioavailability enhancer and a biodegradable polymer, so that the pharmaceutical composition do not have a high initial burst of drug, contain a high content of drug relative to the particle size and have a high bioavailability, and thus, can minimize pain and inflammatory response of patient that may occur when administered to the human body.

TREATING AMYOTROPHIC LATERAL SCLEROSIS HAVING ONSET 24 MONTHS PRIOR TO TREATMENT

Resumen de: MX2025000057A

The present invention relates to the treatment of a ALS patient with oral fausdil at a dose of 180-240 mg/day, wherein the patient is treated beginning at least 24 months following disease onset. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.

REGIMEN FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS HAVING ONSET 24 MONTHS PRIOR TO TREATMENT

Resumen de: WO2024011094A1

The present invention relates to the treatment of an ALS patient having disease onset of at least 24 months prior to initiation of treatment with fausdil. Fasudil is administered at a dose of 60-240 mg/day according to specific treatment regimens. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GENETIC PARKINSON'S DISEASE COMPRISING MITOCHONDRIA AS AN ACTIVE INGREDIENT

Resumen de: KR20250065159A

본 발명에서 파킨슨병을 효과적으로 치료할 수 있는 미토콘드리아 치료제를 제공한다. In vitro 실험 결과, 미토콘드리아 치료제(PN-101)는 신경독소에 의해 야기된 세포 사멸을 현저히 감소시켰다. 또한, PN-101은 LPS에 의해 유도된 항염증 사이토카인 발현을 완화시킴을 확인하였다. 뿐만 아니라, In vivo 실험 결과, PN-101은 DA 뉴런에서 신경 보호 효과를 나타내고, 미세아교세포 활성을 억제함으로써, MPTP 유발된 운동 이상을 개선할 수 있음을 확인하였다. 따라서, 미토콘드리아를 개체에 투여시 파킨슨병을 효과적으로 개선하거나 치료할 수 있음을 확인하였다.

PGAM5 Phmaceutical composition for treating Parkinson's disease containing cell-transducing PGAM5 fusion protein

Resumen de: KR20250064691A

과제: 부작용이 적거나 없으며, 효과가 우수한 파킨슨병 예방 또는 치료용 약제를 제공하는 것. 해결수단: 본 발명은 세포투과성 PGAM5 (포스포글리세레이트 뮤테이즈 5) 융합단백질을 포함하는 파킨슨병 치료용 약학 조성물에 관한 것으로서, 세포 내로 투과된 PGAM5 융합단백질이 MPP+로 유도한 도파민성 세포사멸과 파킨슨 동물 질환 모델에서 세포 보호효능을 발현하는지를 연구하였다. 그 결과, PGAM5 융합단백질은 파킨슨병에서 효과적인 단백질 치료제로서의 가능성이 있음을 확인하였다.

Pharmaceutical composition for treating Alzheimer's disease containing senescent cell-targeting drug as an active ingredient

Resumen de: KR20250063452A

본 발명은 상염색체우성 알츠하이머병에서 노화 조절을 통한 아밀로이드 병리 제거에 최적 시기 및 방법을 확인하여 완성된 것으로서, 노화세포 표적 약물을 진행된 알츠하이머병 환자에 투여하여 알츠하이머병을 치료하는 방법 등을 제공하여 노화 조절을 통한 새로운 패러다임의 알츠하이머병의 치료적 접근을 가능하게 하며, 상기 방법의 효과적인 치료시기를 제공함으로써 진행된 알츠하이머병 환자를 대상으로 하는 다각적 치료방법의 하나로 이용될 수 있다.

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEMENTIA, CONTAINING ISOQUINOLINE DERIVATIVE AS ACTIVE INGREDIENT

Resumen de: WO2025095553A1

A pharmaceutical composition for preventing or treating dementia diseases, containing, as an active ingredient, an isoquinoline derivative compound or a pharmaceutically acceptable salt thereof, of the present invention, does not induce cytotoxicity and can alleviate learning and memory abnormalities in an animal model of Alzheimer's dementia, and thus is expected to be effectively used in the development of therapeutic agents for dementia diseases.

AGENTS FOR USE IN THE TREATMENT OF TAUOPATHIES

Resumen de: WO2025093735A2

The present invention relates to an agent for use in decreasing the level of intracellular phosphorylated tau in neurons, which agent can bind ELAVL4 with a binding affinity of at least - 8.0 kcal/mol. The agent comprises a structural element selected from the group consisting of a steroid backbone, a sugar moiety by glycosidic linkage, an O-linked glucuronide, and a lactone group and is suitably selected from the group of porphyrins, macrolactams, macrolides, vitamin D glucuronides, steroid glucuronides, withanolides, cardenolide glycosides, anthracyclines, ergoloid mesylates, ergotamines and derivates thereof, biphenyls, and piperazines. The administration of said agent leads to a decrease in protein levels of phosphorylated tau in normal neurons treated with the agent as compared to non-treated normal neurons and to a decrease in the Aβ42/Aβ40 ratio in fAD neurons treated with the agent as compared to non-treated fAD neurons. The agent is administered for the treatment of a tauopathy, which may be involved in Alzheimer's disease, frontotemporal dementia, Parkinson's disease or progressive supranuclear palsy and multiple sclerosis.

COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)

Resumen de: US2025146000A1

The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.

ANTI-GAL3 ANTIBODIES AND METHODS OF USE

Resumen de: US2025145722A1

Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.

COMPOSITION COMPRISING A MIXTURE OF DHA AND/OR EPA AND A PHOSPHOLIPID OF PLANT ORIGIN

Resumen de: US2025144159A1

A composition comprising a mixture of DHA and/or EPA in the form of glyceride or ethylester derived from at least one microorganism, such as a microalga, and at least one plant-derived phospholipid, in which the content of DHA and/or EPA in triglyceride form is between 10% and 90% by weight relative to the total weight of the composition, and the content of at least one plant-derived phospholipid, such as phosphatidylcholine, is between 10% and 90% by weight relative to the weight of composition. The method for manufacturing same and to the use thereof, in particular in the treatment of pathologies involving a deficiency of DHA and/or EPA, such as age-related macular degeneration or Alzheimer's disease.

TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITE

Resumen de: US2025144135A1

The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.

Humanized Anti-TDP-43 Binding Molecules and Uses Thereof

Resumen de: US2025145695A1

The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to humanized TDP-43 specific binding molecules, in particular to humanized anti-TDP-43 antibodies or antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).

COMPOSITIONS AND METHODS TO TREAT ALZHEIMER'S DISEASE

Nº publicación: WO2025097123A1 08/05/2025

Solicitante:

BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV AND AGRICULTURAL AND MECHANICAL COLLEGE [US]
BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE

Resumen de: WO2025097123A1

Aspects of the invention are drawn to methods for identifying or treating Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) in a subject. Further aspects of the invention are drawn to methods for screening the presence of an Alzheimer's Disease and/or Alzheimer's Disease and Related Dementias (AD/ADRD) signature.